News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis Todd Neale November 28, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Conference News CRT 2023 In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’ Yael L. Maxwell March 01, 2023
News Daily News New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT Michael O'Riordan December 09, 2021
News Daily News To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped L.A. McKeown June 25, 2019
News Daily News Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina Michael O'Riordan June 30, 2016
News Daily News FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin Michael O'Riordan June 30, 2016
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015